MONTREAL, CANADA (TSX: ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, invites you to participate in a conference call to discuss the company's financial results for the third quarter ended September 30, 2007. The conference call will follow the press release issued earlier on the same day, and will be held on:

Wednesday, November 14, 2007

5:00 p.m. (EST)

To participate in the conference call when dialing within the Montreal area, please dial (514) 861-1531, or (877) 667-7766 for the rest of North America. Outside of North America, please dial (514) 861-1531. Participants are asked to dial 10 minutes prior to the start time.

The conference call will feature Sebastien Gignac, President and Chief Executive Officer, and Jacques Bedard, Chief Financial Officer.

If you are unable to participate, a replay of the conference call will be available until November 22, 2007. To listen to the replay from the Montreal area, please dial (514) 861-2272, or, (800) 408-3053 for the rest of North America. From outside of North America, please dial (514) 861-2272. The access code for the replay is 3241023#.

We look forward to your participation and thank you for your interest in ART Advanced Research Technologies Inc.

About ART

ART Advanced Research Technologies Inc. is a leader in molecular imaging products for the healthcare and pharmaceutical industries. ART has developed products in medical imaging, medical diagnostics, disease research, and drug discovery with the goal of bringing new and better treatments to patients faster. The Optix� optical molecular imaging system, designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs, is distributed directly by ART in North America and Europe and is used by industry and academic leaders worldwide. The SoftScan� optical breast imaging device is designed to improve the diagnosis and treatment of breast cancer. ART is commercializing the SoftScan optical medical imaging device via a global strategic alliance with GE Healthcare, a world leader in mammography and imaging. Finally, the Fenestra� line of molecular imaging contrast products provide image enhancement for a wide range of preclinical Micro CT applications allowing scientists to see greater detail in their imaging studies, with potential extension into other major imaging modalities. The distribution of the Fenestra line of imaging contrast agents is made through GE Healthcare Bio-Science KK in Japan and is sold directly by the Company in the rest of the world. ART's shares are listed on the TSX under the ticker symbol ARA. For more information on ART, visit our website at www.art.ca.

This press release may contain forward-looking statements subject to risks and uncertainties that would cause actual events to differ materially from expectations. These risks and uncertainties are described in the most recent Annual Information Form and the financial statements for the year ended December 31, 2006, available on SEDAR (www.sedar.com).

Contacts: ART Advanced Research Technologies Inc. Jacques Bedard Chief Financial Officer 514-832-0777 jbedard@art.ca www.art.ca

Aclara Resources (TSX:ARA)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Aclara Resources Charts.
Aclara Resources (TSX:ARA)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Aclara Resources Charts.